SUVEN LIFE SCIENCES LTD. - SUVN-G3031 for Cognition in Alzheimer's disease commenced Phase 1 Clinical Trial in USA under US-IND 123179

Suven Life Sciences Ltd has informed BSE regarding a Press Release dated November 03, 2014, titled "SUVN-G3031 for Cognition in Alzheimer's disease commenced Phase 1 Clinical Trial in USA under US-IND 123179".